No profile data available.
Editas Medicine, Inc. (EDIT) is a healthcare company in the additional cancer treatment drugs industry, based in Cambridge, United States, with about 87 full-time employees.
It reported revenue of $40.52 million for fiscal year 2025, up 25.4% from fiscal year 2024, and net income of -$160.06 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $11.89 million, up 232.3% from a year before. Its market capitalization was $445.38 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.
Editas Medicine reported $40.52 million in revenue for fiscal year 2025, up 25.4% from $32.31 million in fiscal year 2024. In Q2 2026 revenue was $11.89 million.
$445.38 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Allogene Therapeutics, Inc. (ALLO), Arvinas, Inc. (ARVN), Autolus Therapeutics plc (AUTL), Aura Biosciences, Inc. (AURA).